NMDA receptor antagonists - Pipeline Insight, 2024

This “NMDA Receptor Antagonists - Pipeline Insight, 2024” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in NMDA Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

NMDA Receptor Antagonists Understanding

NMDA Receptor Antagonists: Overview

The NMDA receptor is an ionotropic receptor that allows for the transfer of electrical signals between neurons in the brain and in the spinal column. N-methyl-D-aspartate receptor is a ligand of glutamate, which is the primary excitatory neurotransmitter in the human brain. The activation of NMDA receptors has been associated with hyperalgesia, neuropathic pain, and reduced functionality of opioid receptors. Molecules that block the NMDA receptor are called NMDA-receptor antagonists. N-methyl-D-aspartate receptors are also expressed across a wide spectrum of non-neuronal cells, including central and peripheral glial cells, endothelium, bone, kidney, pancreas, and others. NMDA-receptor antagonists can be used in the management of chronic pain and Alzheimer's disease. Commercially available NMDA-receptor antagonists include ketamine, dextromethorphan, memantine, and amantadine. The opioids methadone, dextropropoxyphene, and ketobemidone are also antagonists at the NMDA receptor.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence NMDA Receptor Antagonists R&D. The therapies under development are focused on novel approaches for NMDA Receptor Antagonists.

NMDA Receptor Antagonists Emerging Drugs Chapters

This segment of the NMDA Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

NMDA Receptor Antagonists Emerging Drugs

NP-120 (Ifenprodil): Algernon Pharmaceuticals NP-120 (Ifenprodil) is an N-methyl-d-aspartate (NDMA) receptor glutamate receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB). Ifenprodil also exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. NP-120 (Ifenprodil - brand name Cerocal) was initially developed by Sanofi in the 1990s in the French and Japanese markets for the treatment of circulatory disorders. This repurposed drug is under clinical evaluation for the treatment of idiopathic pulmonary fibrosis (IPF) and COVID 2019 infections.

REL 1017: Relmada Therapeutics REL-1017 is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. The drug is currently in late-stage studies as an adjunctive treatment for MDD in adults. In April 2017, the FDA granted Fast Track designation for REL-1017 for the adjunctive treatment of major depressive disorder.

NMDA Receptor Antagonists: Therapeutic Assessment

This segment of the report provides insights about the different NMDA Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on NMDA Receptor Antagonists

There are approx. 25+ key companies which are developing the NMDA Receptor Antagonists. The companies which have their NMDA Receptor Antagonists drug candidates in the most advanced stage, i.e. Phase III include, Relmada Therapeutics.

Phases

This report covers around 25+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

NMDA Receptor Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

NMDA Receptor Antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses NMDA Receptor Antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging NMDA Receptor Antagonists drugs.

NMDA Receptor Antagonists Report Insights

• NMDA Receptor Antagonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

NMDA Receptor Antagonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing NMDA Receptor Antagonists drugs?
• How many NMDA Receptor Antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for NMDA Receptor Antagonists?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the NMDA Receptor Antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for NMDA Receptor Antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Algernon Pharmaceuticals
• Relmada Therapeutics
• UCB
• Avanir Pharmaceuticals
• Axsome Therapeutics
• Seelos Therapeutics
• Pharma Ther
• Cessatech
• ATAI Life Sciences
• Small Pharma
• Bexson Biomedical
• DemeRx

Key Products

• NP-120 (Ifenprodil)
• REL 1017
• Lacosamide
• Deudextromethorphan
• AXS-05
• SLS-002
• Ketamine microneedle patch
• CT-001
• PCN-101
• SPL-801-B
• BB-106
• Ibogaine

This product will be delivered within 1-3 business days.